Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 4950 (2021)

Indigenous venomous snakebites in Switzerland: analysis of reports to the National Poisons Information Centre over 22 years

  • Joan Fuchs
  • Tim Gessner
  • Hugo Kupferschmidt
  • Stefan Weiler
DOI
https://doi.org/10.4414/SMW.2021.w30085
Cite this as:
Swiss Med Wkly. 2021;151:w30085
Published
16.12.2021

Summary

INTRODUCTION: Two venomous snakes, the asp viper (Vipera aspis) and the common adder (Vipera berus) are native to Switzerland. Bites by both vipers cause mainly local effects, but systemic envenomation is possible.

METHODS: We analysed all calls concerning indigenous venomous snakebites recorded at the Swiss National Poisons Information Centre between 1997 and 2018, including all cases with identification by a herpetologist, and/or with compatible symptoms and circumstances of the exposure.

RESULTS: During the study period, 1,364 cases concerned snakebites. One third (466; 34%) were attributed to indigenous vipers. In 243 (52%) patients, medical follow-up information was available, with good causality between exposure and symptoms in 219 (90%) patients. Vipera aspis was identified in 77 of the cases (35%), Vipera berus in 54 (25%), and not further specified vipers in 88 (40%). In over two thirds of the 219 cases (155, 71%) adult patients were affected (male 109, female 46; median age 43 years [range 16–90]). Sixty-four patients were children (male 47, female 16; median age 11 years [range 1.3–15.9]). The highest occurrence of bites was in the summer months. In the majority of patients, the clinical course was mild (94; 43%) or moderate (80; 36%); a lower proportion was either asymptomatic (17; 8%) or exhibited severe symptoms (28; 13%). There were no fatalities reported. The most frequent symptoms were local effects at the bite site with mild (100; 46%) to moderate (56; 25%) swelling, pain (65; 30%) and redness (51; 23%). Gastrointestinal symptoms including nausea (31; 14%), vomiting (47; 22%) and abdominal pain (25; 11%) were also common. Other systemic symptoms included cardiovascular effects (e.g., hypotension (20; 9%) or shock [6; 3%]), neurotoxicity (e.g., visual impairment [5; 2.3%]) and haematotoxicity (e.g., coagulopathy [11; 5%]). Seven (3.2%) patients developed anaphylactic reactions. Antivenom was administered in only 20% (24 with moderate and 19 with severe symptoms) with good resolution of symptoms. The mean duration of hospitalization was 2 days (0–12 days).

CONCLUSION: Snakebites in Switzerland can result in severe symptoms, sometimes necessitating antivenom treatment.

References

  1. Factsheet WH. https://www.who.int/news-room/fact-sheets/detail/snakebite-envenoming accessed 2020 April 4.
  2. Paolino G, Di Nicola MR, Pontara A, Didona D, Moliterni E, Mercuri SR, et al. Vipera snakebite in Europe: a systematic review of a neglected disease. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2247–60. https://doi.org/10.1111/jdv.16722
  3. Website of the. «Koordinationsstelle für Amphibien- und Reptilienschutz in der Schweiz», www.karch.ch, accessed 2020 April 4
  4. Di Nicola MR, Pontara A, Kass GE, Kramer NI, Avella I, Pampena R, et al. Vipers of Major clinical relevance in Europe: Taxonomy, venom composition, toxicology and clinical management of human bites. Toxicology. 2021 Apr;453:152724. https://doi.org/10.1016/j.tox.2021.152724
  5. Meier J, Berney C. Aspisviper (Vipera aspis) und Kreuzotter (Vipera berus): Die medizinisch bedeutsamen Giftschlangen der Schweiz. 1. Teil: Biologie, Verbreitung und Giftzusammensetzung. Swiss Med Forum. 2003;03(32):746-753.
  6. Plate A, Kupferschmidt H, Schneemann M. Giftschlangenbisse in der Schweiz. [Bites of venomous snakes in Switzerland]. Praxis (Bern 1994). 2016;105(12):679-85; quiz 684-5. doi: https://doi.org/10.1024/1661-8157/a002388.
  7. Petite J. Viper bites: treat or ignore? Review of a series of 99 patients bitten by Vipera aspis in an alpine Swiss area. Swiss Med Wkly. 2005 Oct;135(41-42):618–25.
  8. Audebert F, Sorkine M, Bon C. Envenoming by viper bites in France: clinical gradation and biological quantification by ELISA. Toxicon. 1992 May-Jun;30(5-6):599–609. https://doi.org/10.1016/0041-0101(92)90854-X
  9. Meier J, Rauber-Lüthy C, Kupferschmidt H. Aspisviper (Vipera aspis) und Kreuzotter (Vipera berus): Die medizinisch bedeutsamen Giftschlangen der Schweiz - 2.Teil: Vorbeugung, Erste Hilfe und Behandlung von Bissunfällen. Swiss Med Forum. 2003;03(34):780-785. doi: https://doi.org/10.4414/smf.2003.04950
  10. Ferquel E, de Haro L, Jan V, Guillemin I, Jourdain S, Teynié A, et al. Reappraisal of Vipera aspis venom neurotoxicity. PLoS One. 2007 Nov;2(11):e1194. https://doi.org/10.1371/journal.pone.0001194
  11. Zanetti G, Duregotti E, Locatelli CA, Giampreti A, Lonati D, Rossetto O, et al. Variability in venom composition of European viper subspecies limits the cross-effectiveness of antivenoms. Sci Rep. 2018 Jun;8(1):9818. https://doi.org/10.1038/s41598-018-28135-0
  12. Jollivet V, Hamel JF, de Haro L, Labadie M, Sapori JM, Cordier L, et al. European viper envenomation recorded by French poison control centers: A clinical assessment and management study. Toxicon. 2015 Dec;108:97–103. https://doi.org/10.1016/j.toxicon.2015.09.039
  13. Lonati D, Giampreti A, Rossetto O, Petrolini VM, Vecchio S, Buscaglia E, et al. Neurotoxicity of European viperids in Italy: Pavia Poison Control Centre case series 2001-2011. Clin Toxicol (Phila). 2014 Apr;52(4):269–76. https://doi.org/10.3109/15563650.2014.904046
  14. Malina T, Krecsák L, Korsós Z, Takács Z. Snakebites in Hungary—epidemiological and clinical aspects over the past 36 years. Toxicon. 2008;51(6):943-51. RE:view. https://doi.org/10.1016/j.toxicon.2007.12.001
  15. Giribaldi J, Kazandjian T, Amorim FG, Whiteley G, Wagstaff SC, Cazals G, et al. Venomics of the asp viper Vipera aspis aspis from France. J Proteomics. 2020 Apr;218:103707. https://doi.org/10.1016/j.jprot.2020.103707
  16. Karlson-Stiber C, Salmonson H, Persson H. A nationwide study of Vipera berus bites during one year-epidemiology and morbidity of 231 cases. Clin Toxicol (Phila). 2006;44(1):25–30. https://doi.org/10.1080/15563650500394597
  17. Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–13. https://doi.org/10.3109/15563659809028940
  18. Stahel E, Wellauer R, Freyvogel TA. Vergiftungen durch einheimische Vipern (Vipera berus und Vipera aspis). Eine retrospektive Studie an 113 Patienten [Poisoning by domestic vipers (Vipera berus and Vipera aspis). A retrospective study of 113 patients] [German.]. Schweiz Med Wochenschr. 1985 Jun;115(26):890–6.
  19. Ruha AM, Kleinschmidt KC, Greene S, Spyres MB, Brent J, Wax P, et al.; ToxIC Snakebite Study Group. Snakebite Study Group. The epidemiology, clinical course, and management of snakebites in the North American Snakebite Registry. J Med Toxicol. 2017 Dec;13(4):309–20. https://doi.org/10.1007/s13181-017-0633-5
  20. Boels D, Hamel JF, Bretaudeau Deguigne M, Harry P. European viper envenomings: assessment of Viperfav™ and other symptomatic treatments. Clin Toxicol (Phila). 2012 Mar;50(3):189–96. https://doi.org/10.3109/15563650.2012.660695
  21. Frangides CY, Koulouras V, Kouni SN, Tzortzatos GV, Nikolaou A, Pneumaticos J, et al. Snake venom poisoning in Greece. Experiences with 147 cases. Eur J Intern Med. 2006 Jan;17(1):24–7. https://doi.org/10.1016/j.ejim.2005.10.001
  22. Ochola FO, Okumu MO, Muchemi GM, Mbaria JM, Gikunju JK, Onono JO, et al. Epidemiology of snake bites in selected areas of Kenya. Pan Afr Med J. 2018 Apr;29:217. https://doi.org/10.11604/pamj.2018.29.217.15366
  23. Lamb T, Stewart D, Warrell DA, Lalloo DG, Jagpal P, Jones D, et al. Moderate-to-severe Vipera berus envenoming requiring ViperaTAb antivenom therapy in the UK. Clin Toxicol (Phila). 2021 Nov;59(11):992–1001. https://doi.org/10.1080/15563650.2021.1891245
  24. Jaramillo JD, Hakes NA, Tennakoon L, Spain D, Forrester JD. The “T’s” of snakebite injury in the USA: fact or fiction? Trauma Surg Acute Care Open. 2019 Oct;4(1):e000374. https://doi.org/10.1136/tsaco-2019-000374
  25. Valenta J, Stach Z, Stříteský M, Michálek P. Common viper bites in the Czech Republic - epidemiological and clinical aspects during 15 year period (1999-2013). Prague Med Rep. 2014;115(3-4):120–7. https://doi.org/10.14712/23362936.2014.42
  26. Chippaux JP, Saz-Parkinson Z, Amate Blanco JM. Epidemiology of snakebite in Europe: comparison of data from the literature and case reporting. Toxicon. 2013 Dec;76:206–13. https://doi.org/10.1016/j.toxicon.2013.10.004
  27. Levine M, Ruha AM, Wolk B, Caravati M, Brent J, Campleman S, et al.; ToxIC North American Snakebite Study Group. North American Snakebite Study Group. When it comes to snakebites, kids are little adults: a comparison of adults and children with Rattlesnake bites. J Med Toxicol. 2020 Oct;16(4):444–51. https://doi.org/10.1007/s13181-020-00776-6
  28. Marano M, Pisani M, Zampini G, Pontrelli G, Roversi M. Acute exposure to European viper bite in children: advocating for a pediatric approach. Toxins (Basel). 2021 May;13(5):330. https://doi.org/10.3390/toxins13050330
  29. Personne M, Hulten P. The need of a second antivenom dose after snake bites by Vipera berus. (2017) 37th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 16–19 May 2017, Basel, Switzerland, Clin Toxicol (Phila). 55:5, 488, doi: https://doi.org/10.1080/15563650.2017.1309792

Most read articles by the same author(s)